CXCL8 and breast cancer: As shown in Figure 4, TNF-α, IL-6, and IL-8 were significantly reduced after 6 months in the SHD group, but not in the control group, and this indicated that SHD can significantly improve the inflammatory response of patients with breast cancer treated with endocrine therapy.